Science at the Edge
Engineering Seminar
October 11th, 2013
11:30 a.m., Room1400 Biomedical and
Physical Sciences Building
Refreshments served at 11:15 a.m.
Michael Snyder
Department of Genetics
Stanford University School of
Medicine
Personalized Medicine: Personal
Omics Profiling of Healthy and Disease States
Abstract
Personalized
medicine is expected to benefit from the combination of
genomic information with the global monitoring of molecular
components and physiological states. To ascertain whether this
can be achieved, we determined the whole genome sequence of an
individual at high accuracy and performed an integrated
Personal Omics Profiling (iPOP) analysis, combining genomic,
transcriptomic, proteomic, metabolomic, and autoantibodyomic
information, over a 38-month period that included healthy and
two virally infected states. Our iPOP analysis of blood
components revealed extensive, dynamic and broad changes in
diverse molecular components and biological pathways across
healthy and disease conditions. Importantly, genomic
information was also used to estimate medical risks, including
Type 2 Diabetes, whose onset was observed during the course of
our study. Our study demonstrates that longitudinal personal
omics profiling can relate genomic information to global
functional omics activity for physiological and medical
interpretation of healthy and disease states.
Bio
Michael Snyder is the Stanford
Ascherman Professor, Chair of Genetics and the Director of the
Center of Genomics and Personalized Medicine. He received his
Ph.D. from the California Institute of Technology and
postdoctoral training at Stanford University. He is a leader
in the field of functional genomics and proteomics, and one of
the major participants of the ENCODE project. His laboratory
study was the first to perform a large-scale functional
genomics project in any organism, and has launched many
technologies in genomics and proteomics. These including the
development of proteome chips, high resolution tiling arrays
for the entire human genome, methods for global mapping of
transcription factor binding sites (ChIP-chip now replaced by
ChIP-seq), paired end sequencing for mapping of structural
variation in eukaryotes, de novo genome sequencing of genomes
using high throughput technologies and RNA-Seq. These
technologies have been used for characterizing genomes,
proteomes and regulatory networks. Seminal findings from the
Snyder laboratory include; the discovery that much more of the
human genome is transcribed and contains regulatory
information than was previously appreciated, and a high
diversity of transcription factor binding occurs both between
and within species. He has also combined different
state-of–the-art omics technologies to perform the first
longitudinal detailed integrative personal omics profile
(iPOP) of person and used this to assess disease risk and
monitor disease states for personalized medicine. He is a
co-founder of several biotechnology companies including;
Protometrix (now part of Life Technologies), Affomix (now part
of Illumina), Excelix, and Personalis, and he presently serves
on the board of a number of companies.
For further
information please contact Prof. Christina Chan, Department of
Chemical Engineering and Materials Science at [log in to unmask]
Persons with disabilities have the right
to request and receive reasonable accommodation. Please call the
Department of Chemical Engineering and Materials Science at
355-5135 at least one day prior to the seminar; requests
received after this date will be met when possible.